Walt R P, Male P J, Rawlings J, Hunt R H, Milton-Thompson G J, Misiewicz J J
Gut. 1981 Jan;22(1):49-54. doi: 10.1136/gut.22.1.49.
Twenty-four hour intragastric acidity and nocturnal acid secretion were measured in 10 males with duodenal ulcer in four separate 24 hour studies, during which the subjects ate normal meals, had unrestricted physical activity, and consumed their customary quantities of tobacco. The medication consisted of either placebo, cimetidine 200 mg tds and 400 mg at night, or ranitidine 150 mg bd, or 200 mg bd. Ranitidine 150 mg bd decreased mean 24 hour hydrogen ion activity from 41.8 mmol/l to 13.1 mmol/l (-69%, P less than 0.001) and nocturnal acid output from 6.1 mmol/h to 0.6 mmol/h (-90%, P less than 0.01). This degree of inhibition was significantly greater than that due to cimetidine (P less than 0.001 for 24 hours acidity, less than 0.05 for night time acid output). Plasma concentrations of ranitidine were greater than the IC50 for more than eight hours after the 150 mg dose. Ranitidine 200 mg conferred no additional advantage. Ranitidine 150 mg bd should be tested in therapeutic trials.
在四项独立的24小时研究中,对10名十二指肠溃疡男性患者进行了24小时胃内酸度和夜间酸分泌测量。在此期间,受试者正常饮食,进行无限制的体力活动,并按习惯量吸烟。药物治疗包括安慰剂、西咪替丁每日三次每次200毫克及夜间400毫克、雷尼替丁每日两次每次150毫克或每日两次每次200毫克。雷尼替丁每日两次每次150毫克可使平均24小时氢离子活性从41.8毫摩尔/升降至13.1毫摩尔/升(-69%,P<0.001),夜间酸分泌量从6.1毫摩尔/小时降至0.6毫摩尔/小时(-90%,P<0.01)。这种抑制程度明显大于西咪替丁所致(24小时酸度P<0.001,夜间酸分泌量P<0.05)。150毫克剂量的雷尼替丁给药后,血浆浓度超过半数抑制浓度(IC50)的时间超过8小时。雷尼替丁每日两次每次200毫克未显示出额外优势。雷尼替丁每日两次每次150毫克应在治疗试验中进行测试。